ES2662418T3 - Agentes de unión a TNF mejorados - Google Patents

Agentes de unión a TNF mejorados Download PDF

Info

Publication number: ES2662418T3
Authority: ES; Spain
Prior art keywords: amino acid; seq; disclosure; tnf; sequence
Prior art date: 2015-11-12
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

ES16798122.4T

Other languages

English (en)

Spanish (es)

Inventor

Marie-Ange Buyse

Joachim Boucneau

Peter Casteels

Gino Van Heeke

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Ablynx NV

Original Assignee

Ablynx NV

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-11-12

Filing date

2016-11-14

Publication date

2018-04-06

2016-11-14 Application filed by Ablynx NV filed Critical Ablynx NV

2018-04-06 Application granted granted Critical

2018-04-06 Publication of ES2662418T3 publication Critical patent/ES2662418T3/es

Status Active legal-status Critical Current

2036-11-14 Anticipated expiration legal-status Critical

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Dermatology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicinal Preparation (AREA)
Organic Insulating Materials (AREA)
Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Treatment Of Liquids With Adsorbents In General (AREA)

ES16798122.4T 2015-11-12 2016-11-14 Agentes de unión a TNF mejorados Active ES2662418T3 (es)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201562254375P	2015-11-12	2015-11-12
US201562254375P		2015-11-12
PCT/EP2016/077595 WO2017081320A1 (en)	2015-11-12	2016-11-14	Improved tnf binders

Publications (1)

Publication Number	Publication Date
ES2662418T3 true ES2662418T3 (es)	2018-04-06

Family

ID=57348648

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES16798122.4T Active ES2662418T3 (es)	2015-11-12	2016-11-14	Agentes de unión a TNF mejorados

Country Status (37)

Country	Link
US (2)	US10544211B2 (2)
EP (2)	EP3191511B1 (2)
JP (2)	JP6962915B2 (2)
KR (2)	KR20240029115A (2)
CN (1)	CN108473563B (2)
AU (2)	AU2016352943B2 (2)
BR (1)	BR112018009714A8 (2)
CA (2)	CA3005085C (2)
CL (1)	CL2018001291A1 (2)
CO (1)	CO2018005915A2 (2)
CR (1)	CR20180311A (2)
CY (1)	CY1120303T1 (2)
DK (1)	DK3191511T3 (2)
DO (1)	DOP2018000122A (2)
EC (1)	ECSP18042569A (2)
ES (1)	ES2662418T3 (2)
GT (1)	GT201800095A (2)
HK (1)	HK1248716A1 (2)
HR (1)	HRP20171949T1 (2)
HU (1)	HUE035805T2 (2)
IL (2)	IL310373A (2)
LT (1)	LT3191511T (2)
MA (1)	MA41653A (2)
MD (1)	MD3191511T2 (2)
ME (1)	ME02954B (2)
MX (1)	MX385207B (2)
NO (1)	NO2768984T3 (2)
PE (1)	PE20181317A1 (2)
PH (1)	PH12018501025A1 (2)
PL (1)	PL3191511T3 (2)
PT (1)	PT3191511T (2)
RS (1)	RS56676B1 (2)
SG (1)	SG11201803975SA (2)
SI (1)	SI3191511T1 (2)
SM (1)	SMT201700590T1 (2)
TN (1)	TN2018000159A1 (2)
WO (1)	WO2017081320A1 (2)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11644471B2 (en)	2010-09-30	2023-05-09	Ablynx N.V.	Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
DK2723769T4 (da)	2011-06-23	2022-09-05	Ablynx Nv	Teknikker til at forudsige, påvise og reducere uspecifik proteininterferens i assays, som involverer variable immunglobulin-enkeltdomæner
KR20250099289A (ko)	2014-05-16	2025-07-01	아블린쓰 엔.브이.	개선된 면역글로불린 가변 도메인
PL3248986T3 (pl)	2014-05-16	2022-05-16	Ablynx Nv	Domeny zmienne immunoglobuliny
NO2768984T3 (2) *	2015-11-12	2018-06-09
GB201522394D0 (en)	2015-12-18	2016-02-03	Ucb Biopharma Sprl	Antibodies
JP7657797B2 (ja)	2019-12-06	2025-04-07	アブリンクスエン．ヴェー．	ＴＮＦαおよびＩＬ－２３を標的化する免疫グロブリン単一可変ドメインを含むポリペプチド
PH12022551231A1 (en) *	2019-12-06	2023-07-31	Ablynx Nv	Polypeptides comprising immunoglobulin single variable domains targeting tnfa and ox40l
CN112300289B (zh) *	2019-12-30	2022-06-10	中国药科大学	RGD4C融合抗TNFα纳米抗体蛋白、制备方法及其应用
KR20230123497A (ko) *	2020-12-18	2023-08-23	아블린쓰 엔.브이.	IL-6 및 TNF-α를 표적화하는 면역글로불린 단일 가변도메인을 포함하는 폴리펩티드
TW202330596A (zh) *	2021-11-29	2023-08-01	大陸商江蘇恆瑞醫藥股份有限公司	經修飾的蛋白或多肽
AU2023373192A1 (en) *	2022-11-04	2025-04-17	St. Jude Children's Research Hospital, Inc.	Nlrp12 and nlrc5 modulators and methods for using the same to modulate diseases
AR131494A1 (es)	2022-12-23	2025-03-26	Ablynx Nv	Vehículos de conjugación a base de proteína
JP2026506075A (ja)	2023-02-17	2026-02-20	アブリンクスエン．ヴェー．	新生児型ｆｃ受容体に結合するポリペプチド

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU701578B2 (en)	1992-08-21	1999-02-04	Vrije Universiteit Brussel	Immunoglobulins devoid of light chains
EP0739981A1 (en)	1995-04-25	1996-10-30	Vrije Universiteit Brussel	Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
BR9813276A (pt)	1997-10-27	2000-08-22	Unilever Nv	Proteìna multivalente de ligação de antìgeno, sequências de nucleotìdeos, vetor de expressão, célula hospedeira, processo para preparação de proteìna multivalente de ligação de antìgeno, e, uso da mesma
AU3295299A (en)	1998-02-19	1999-09-06	Xcyte Therapies, Inc.	Compositions and methods for regulating lymphocyte activation
US9321832B2 (en)	2002-06-28	2016-04-26	Domantis Limited	Ligand
US20060002935A1 (en)	2002-06-28	2006-01-05	Domantis Limited	Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
CA2505316C (en) *	2002-11-08	2014-08-05	Ablynx N.V.	Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
WO2005044858A1 (en)	2003-11-07	2005-05-19	Ablynx N.V.	Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor
EP1587838B1 (en)	2003-01-10	2015-04-15	Ablynx N.V.	Therapeutic polypeptides, homologues thereof, fragments thereof and their use in modulating platelet-mediated aggregation
CN1845938B (zh)	2003-06-30	2010-05-26	杜门蒂斯有限公司	多肽
WO2006040153A2 (en)	2004-10-13	2006-04-20	Ablynx N.V.	Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
CA2588892A1 (en)	2004-12-02	2006-06-08	Dormantis Limited	Anti-il-1r1 single domain antibodies and therapeutic uses
WO2006122787A1 (en) *	2005-05-18	2006-11-23	Ablynx Nv	Serum albumin binding proteins
ES2852423T3 (es)	2005-05-20	2021-09-13	Ablynx Nv	NanobodiesTM mejorados para el tratamiento de trastornos mediados por agregación
DE102005023617A1 (de) *	2005-05-21	2006-11-23	Aspre Ag	Verfahren zum Mischen von Farben in einem Display
WO2007025977A2 (en)	2005-08-30	2007-03-08	Actogenix Nv	Anti-tnf alpha producing lactic acid bacteria for the treatment of chronic enterocolitis
EA200801166A1 (ru)	2005-12-01	2008-12-30	Домантис Лимитед	Форматы конкурентного доменного антитела, которые связываются с рецептором интерлейкина 1 первого типа
CA2632866A1 (en)	2005-12-01	2007-06-07	Domantis Limited	Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1
FR2894741B1 (fr)	2005-12-08	2009-12-04	Centre Nat Etd Spatiales	Chaine de reception par satellite
WO2007085814A1 (en)	2006-01-24	2007-08-02	Domantis Limited	Fusion proteins that contain natural junctions
EP2057191A1 (en)	2006-08-18	2009-05-13	Ablynx N.V.	Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
CA2671581A1 (en)	2006-12-05	2008-06-12	Ablynx N.V.	Peptides capable of binding to serum proteins
CN101796072B (zh)	2007-05-24	2014-09-24	埃博灵克斯股份有限公司	用于治疗骨疾病和病症的针对rank-l的氨基酸序列以及包括其的多肽
EP2220120A2 (en)	2007-11-27	2010-08-25	Ablynx N.V.	Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
DE102008023620A1 (de)	2008-05-15	2009-11-19	Mettler-Toledo (Albstadt) Gmbh	Funktionseinheit mit einer aufrufbaren Funktion und Verfahren zu deren Aufruf
NZ589036A (en)	2008-05-16	2012-07-27	Ablynx Nv	AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME
CN102405236A (zh) *	2009-02-19	2012-04-04	葛兰素集团有限公司	改进的抗-tnfr1多肽，抗体可变结构域和拮抗剂
NZ595461A (en)	2009-04-10	2013-01-25	Ablynx Nv	Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
WO2010130832A2 (en)	2009-05-15	2010-11-18	Ablynx N.V.	Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions
JP2012532620A (ja)	2009-07-16	2012-12-20	グラクソグループリミテッド	改良型抗血清アルブミン結合単一可変ドメイン
US9120855B2 (en)	2010-02-10	2015-09-01	Novartis Ag	Biologic compounds directed against death receptor 5
CN103917560B (zh)	2011-03-28	2017-05-24	埃博灵克斯股份有限公司	双特异性抗‑cxcr7免疫球蛋白单可变结构域
CN106046168A (zh)	2011-06-23	2016-10-26	埃博灵克斯股份有限公司	结合血清白蛋白的蛋白
DK2723769T4 (da) *	2011-06-23	2022-09-05	Ablynx Nv	Teknikker til at forudsige, påvise og reducere uspecifik proteininterferens i assays, som involverer variable immunglobulin-enkeltdomæner
SG2014010482A (en) *	2011-08-17	2014-04-28	Glaxo Group Ltd	Modified proteins and peptides
WO2014111550A1 (en)	2013-01-17	2014-07-24	Glaxosmithkline Intellectual Property Development Limited	Modified anti-serum albumin binding proteins
PL3248986T3 (pl)	2014-05-16	2022-05-16	Ablynx Nv	Domeny zmienne immunoglobuliny
NO2768984T3 (2)	2015-11-12	2018-06-09
JP7540877B2 (ja) *	2016-02-12	2024-08-27	アブリンクスエン．ヴェー．	免疫グロブリン単一可変ドメインの生成方法

2012
- 2012-10-19 NO NO12841612A patent/NO2768984T3/no unknown
2016
- 2016-11-13 MA MA041653A patent/MA41653A/fr unknown
- 2016-11-14 SG SG11201803975SA patent/SG11201803975SA/en unknown
- 2016-11-14 ME MEP-2017-291A patent/ME02954B/me unknown
- 2016-11-14 KR KR1020247005963A patent/KR20240029115A/ko active Pending
- 2016-11-14 IL IL310373A patent/IL310373A/en unknown
- 2016-11-14 EP EP16798122.4A patent/EP3191511B1/en active Active
- 2016-11-14 MD MDE20170066T patent/MD3191511T2/ro unknown
- 2016-11-14 SM SM20170590T patent/SMT201700590T1/it unknown
- 2016-11-14 IL IL259269A patent/IL259269B2/en unknown
- 2016-11-14 MX MX2018005992A patent/MX385207B/es unknown
- 2016-11-14 KR KR1020187016731A patent/KR102641194B1/ko active Active
- 2016-11-14 BR BR112018009714A patent/BR112018009714A8/pt active IP Right Grant
- 2016-11-14 TN TNP/2018/000159A patent/TN2018000159A1/en unknown
- 2016-11-14 CR CR20180311A patent/CR20180311A/es unknown
- 2016-11-14 PL PL16798122T patent/PL3191511T3/pl unknown
- 2016-11-14 CA CA3005085A patent/CA3005085C/en active Active
- 2016-11-14 WO PCT/EP2016/077595 patent/WO2017081320A1/en not_active Ceased
- 2016-11-14 JP JP2018524836A patent/JP6962915B2/ja active Active
- 2016-11-14 HR HRP20171949TT patent/HRP20171949T1/hr unknown
- 2016-11-14 HU HUE16798122A patent/HUE035805T2/en unknown
- 2016-11-14 PE PE2018000766A patent/PE20181317A1/es unknown
- 2016-11-14 US US15/501,011 patent/US10544211B2/en active Active
- 2016-11-14 DK DK16798122.4T patent/DK3191511T3/en active
- 2016-11-14 CN CN201680076588.6A patent/CN108473563B/zh active Active
- 2016-11-14 ES ES16798122.4T patent/ES2662418T3/es active Active
- 2016-11-14 SI SI201630013T patent/SI3191511T1/en unknown
- 2016-11-14 EP EP17184686.8A patent/EP3266798A3/en not_active Withdrawn
- 2016-11-14 PT PT167981224T patent/PT3191511T/pt unknown
- 2016-11-14 LT LTEP16798122.4T patent/LT3191511T/lt unknown
- 2016-11-14 AU AU2016352943A patent/AU2016352943B2/en active Active
- 2016-11-14 CA CA3234178A patent/CA3234178A1/en active Pending
- 2016-11-14 RS RS20171299A patent/RS56676B1/sr unknown
2017
- 2017-03-13 US US15/456,824 patent/US9745372B2/en active Active
- 2017-12-01 HK HK18108106.4A patent/HK1248716A1/en unknown
- 2017-12-19 CY CY20171101330T patent/CY1120303T1/el unknown
2018
- 2018-05-11 GT GT201800095A patent/GT201800095A/es unknown
- 2018-05-11 CL CL2018001291A patent/CL2018001291A1/es unknown
- 2018-05-11 DO DO2018000122A patent/DOP2018000122A/es unknown
- 2018-05-15 PH PH12018501025A patent/PH12018501025A1/en unknown
- 2018-06-05 EC ECIEPI201842569A patent/ECSP18042569A/es unknown
- 2018-06-08 CO CONC2018/0005915A patent/CO2018005915A2/es unknown
2021
- 2021-10-14 JP JP2021168871A patent/JP7357038B2/ja active Active
2023
- 2023-01-10 AU AU2023200113A patent/AU2023200113A1/en active Pending

Also Published As

Publication number	Publication date
CA3234178A1 (en)	2017-05-18
MX385207B (es)	2025-03-04
MD3191511T2 (ro)	2018-03-31
JP2022020666A (ja)	2022-02-01
HK1248716A1 (en)	2018-10-19
KR20240029115A (ko)	2024-03-05
TN2018000159A1 (en)	2019-10-04
CN108473563B (zh)	2022-06-14
US10544211B2 (en)	2020-01-28
PH12018501025A1 (en)	2019-01-28
HUE035805T2 (en)	2018-05-28
SMT201700590T1 (it)	2018-01-11
US9745372B2 (en)	2017-08-29
AU2016352943B2 (en)	2022-10-20
KR20180083382A (ko)	2018-07-20
GT201800095A (es)	2019-08-15
PL3191511T3 (pl)	2018-03-30
EP3191511A1 (en)	2017-07-19
CA3005085A1 (en)	2017-05-18
US20170190769A1 (en)	2017-07-06
SI3191511T1 (en)	2018-01-31
MX2018005992A (es)	2019-01-31
CL2018001291A1 (es)	2018-09-14
SG11201803975SA (en)	2018-06-28
RS56676B1 (sr)	2018-03-30
BR112018009714A8 (pt)	2019-02-26
DK3191511T3 (en)	2018-01-08
CN108473563A (zh)	2018-08-31
IL259269A (en)	2018-07-31
EP3266798A3 (en)	2018-03-28
JP7357038B2 (ja)	2023-10-05
IL259269B1 (en)	2024-03-01
JP2019506839A (ja)	2019-03-14
US20170267752A1 (en)	2017-09-21
CY1120303T1 (el)	2019-07-10
PE20181317A1 (es)	2018-08-14
PT3191511T (pt)	2017-11-30
RU2018120524A (ru)	2019-12-13
CA3005085C (en)	2024-09-10
LT3191511T (lt)	2018-01-10
AU2023200113A1 (en)	2023-02-16
IL310373A (en)	2024-03-01
AU2016352943A1 (en)	2018-06-07
MA41653A (fr)	2018-01-09
WO2017081320A1 (en)	2017-05-18
JP6962915B2 (ja)	2021-11-10
IL259269B2 (en)	2024-07-01
NO2768984T3 (2)	2018-06-09
HRP20171949T1 (hr)	2018-01-26
DOP2018000122A (es)	2018-09-30
EP3266798A2 (en)	2018-01-10
CR20180311A (es)	2018-10-18
BR112018009714A2 (en)	2018-11-21
RU2018120524A3 (2)	2020-09-24
ME02954B (me)	2018-07-20
ECSP18042569A (es)	2018-07-31
EP3191511B1 (en)	2017-09-20
KR102641194B1 (ko)	2024-02-26
CO2018005915A2 (es)	2018-06-20

Publication	Publication Date	Title
ES2662418T3 (es)	2018-04-06	Agentes de unión a TNF mejorados
US12428497B2 (en)	2025-09-30	Multispecific antibody constructs
CN103619878B (zh)	2016-10-26	结合血清白蛋白的蛋白
BR112019016490A2 (pt)	2020-04-07	anticorpo humanizado para tratar ou prevenir distúrbios cognitivos, processo para produzir o mesmo e agente para tratar ou prevenir distúrbios cognitivos com o uso do mesmo
KR20250011922A (ko)	2025-01-22	신규한 차폐된 항체
RU2774823C2 (ru)	2022-06-23	Усовершенствованные агенты, связывающие tnf
HK1238660A1 (en)	2018-05-04	Improved tnf binders
HK1238660B (en)	2018-10-05	Improved tnf binders
TW202413435A (zh)	2024-04-01	融合蛋白的藥物組成物及其使用方法
WO2026086930A1 (zh)	2026-04-30	Tl1a结合分子及其应用
TW202031681A (zh)	2020-09-01	經工程處理之Fc